| |
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
Today’s Big NewsJun 30, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| By Nick Paul Taylor AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. |
|
|
|
By Kevin Dunleavy Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being laid off, according to a Massachusetts Worker Adjustment and Retraining Notification. |
By Andrea Park,Nick Paul Taylor,Zoey Becker The top 10 meds were responsible for about a third of all pharmaceutical advertising spending in 2024; MediaRadar reported more than $10.1 billion spent marketing all prescription drugs last year, a year-over-year increase of about 2%. |
By Gabrielle Masson Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the investor has failed to meet its monetary commitments and warning of immediate consequences for its biotech portfolio. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more.
|
|
By Angus Liu The Orphan Cures Act has been added back into the Senate version of President Donald Trump's “big, beautiful bill” after being left out in the chamber’s first rendition. |
By Gabrielle Masson Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according to the pharma. |
By Andrea Park A new survey from Takeda due to be presented at the ESMO Gastrointestinal Cancers Congress in Spain this week highlights significant gaps in the treatment experiences of people with metastatic colorectal cancer. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Fraiser Kansteiner Hikma plans to throw down $1 billion by 2030 to expand its manufacturing and R&D firepower in the U.S., where the company has been in operation since 1991. The investment plan plays into the Trump administration’s touted aim to increase production of drugs for U.S. patients on U.S. soil, with Hikma branding the initiative “America Leans on Hikma: Quality Medicines Manufactured in the USA.” |
By Nick Paul Taylor A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price. |
By Zoey Becker Unicycive has already lined up a second manufacturer after the FDA flagged deficiencies at a third-party vendor the company had hired to make its oxylanthanum carbonate (OLC) drug product. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
| Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
